Background: Placebo control in allergen immunotherapy (AIT) trials presents ethical
| INTRODUC TI ON
Placebo control in allergen immunotherapy (AIT) trials poses methodological and ethical challenges. Fewer local side effects in the placebo arm than in the active arm may impact blinding.
1 Ethical considerations, especially in pediatric populations, are also present since not all patients can benefit from active therapy during long trials.
2
ARIA-GA 2 LEN statement (2011) introduced the theoretical concept of an "active allergen placebo," that is, a placebo with the other season's allergen. In this study design concept, patients allergic to 2 different allergens are randomized to AIT with 1 of 2 allergens, with the untargeted treatment serving as control for the targeted treatment. 1 Targeted treatment effect in this context is defined as the AIT effect directed at 1 of the 2 patient's allergies (eg, grass AIT effect on the grass allergy-direct or expected effect), while the untargeted treatment effect is the effect on the other allergy (eg, grass AIT effect on the birch allergy-indirect or unexpected effect). In this proposed design, all patients would benefit from active treatment. This trial design was used previously in a post hoc analysis of a study involving few patients suffering from house dust mite and timothy grass pollen allergy. 3 However, to further validate the trial design in AIT trials, there is a need to investigate how specific the AIT is and to what extent treatment effects are also present in the untargeted treatment groups. Also, it should be assessed whether such studies can be done in patients suffering from distinct pollen allergens.
To address these questions, we designed a prospective, double- 
| ME THODS

| Trial design
This was a multicenter, randomized (1:1), double-blind, controlled phase IV trial with 2-active parallel groups, conducted in Germany in 15 investigational sites (10 hospital clinics and 5 office practices) between April 2014 and November 2015 (EudraCT: 2013-003095-12).
| Participants
Eligibility criteria (all of which needed to be met for inclusion) were as follows: patients (male/female) aged 18-65 years, suffering from
G R A P H I C A L A B S T R A C T
An "active allergen placebo" design can overcome limitations faced by classical placebo, reduces ethical concerns, improves blinding, and allows longer trial durations. Dual-allergic patients were challenged with both allergens in an allergen challenge chamber before and after allergen immunotherapy (AIT); active untargeted treatment effect served as control. Results confirmed the specificity of AIT; therefore, untargeted AIT is an adequate control for targeted AIT. ACC: allergen challenge chamber; AIT: allergen immunotherapy; AUC: area under the curve; B-B: birch-on-birch treatment effect (targeted); B-G: birch-on-grass treatment effect (untargeted); CI: confidence interval; G-B: grass-on-birch treatment effect (untargeted); G-G: grass-ongrass treatment effect (targeted); TNSS: total nasal symptom score. 
| Interventions
At screening visit, a skin prick test (see Supporting Information for details), immunological profile assessment (see Supporting Information), and lung function test (peak expiratory flow [PEF]) were performed.
Before randomization, 2 distinct pretreatment ACC visits ( Figure 1) were performed for the 2 different allergens. Patients were then randomized to receive either grass or birch AIT. After the treatment, 2 additional distinct post-treatment ACC visits were performed. At final visit, ≥ 5 days after the last ACC, the following outcomes were evaluated: adverse events (AEs), laboratory tests, concomitant medication, tolerability, PEF (safety measurement per investigator judgment), and specific immunoglobulin G 4 (IgG 4 ) timothy grass and birch titers.
| Immunotherapy
Investigational Medicinal Products (IMPs) were 100% aluminum-ad- The TNSS was the sum of scores for nasal congestion, rhinorrhea, nasal itching, and sneezing, using a 4-point scale (0-3). 
| Immunological parameters
Immunological AIT effects were assessed by analyzing the serum concentrations of timothy grass and birch-specific IgG 4 before and after treatment using ImmunoCAP (ThermoFisher Scientific).
| Numerical rating scale (NRS)
The patients rated symptoms at home using an NRS (discrete values: 
| Outcomes
Treatment effect, on targeted and untargeted AIT groups, was defined • Between AIT groups, to assess utility of the "active allergen placebo": G-G vs G-B; and B-B vs B-G;
• Within AIT groups, to assess specificity of the ACC measurement:
G-G vs B-G; and B-B vs G-B; • Combined: (G-G & B-B: average of both effects) vs (B-G & G-B).
The change from pre-to post-treatment in allergen-specific IgG 4
was also investigated. Severity of allergy symptoms was measured during pollen seasons, and NRS scores were compared between birch and pollen seasons (within each AIT group). Safety outcomes included AEs, laboratory tests, vital signs, and assessment of overall tolerability by investigators and patients.
| Safety measurements
Safety evaluation was based on AEs, lung function tests, laboratory tests, and physical examination. Tolerability was assessed by the investigator and patients on a 5-point Likert scale.
| Medications
Rescue medications were permitted for ACC related symptoms, which included salbutamol, topical levocabastine nasal spray and eye drops, and loratadine or cetirizine tablets. Established symptomatic medications during the pollen season were allowed.
Intermittent treatment with inhaled corticosteroids was allowed at ≤ 500 μg/day beclomethasone-dipropionate (or equivalent) for patients with asthma.
| Randomization and blinding
To ensure a 1:1 randomization ratio within each trial site, the ran- 
| Statistical methods
The primary endpoint was analyzed for the FAS (confirmatory) and PPS (exploratory, sensitivity analysis). For the primary and secondary analyses, a hierarchical test procedure was applied. Since grass AIT data in an ACC were available, 6 the hypothesis H 01 : (μ G-G = 0 vs 
| Ethical conduct of the trial
The trial was conducted in accordance with the ethical principles 
| RE SULTS
Of the 269 patients screened, 95 were randomized to grass AIT (N = 47) or birch AIT (N = 48) ( Figure 2 ). Of the 137 patients excluded due to inclusion/exclusion criteria, 28 patients had low symptoms (AUC adj TNSS < 10) in the pretreatment ACC (4 patients during grass ACC and 24 patients during birch ACC). AIT groups were well balanced in demographic characteristics, and in total and specific IgE (Table 1) . The majority of patients (n = 68; 71.6%) had no asthma reported, and about one-third (n = 27; 28.4%) had controlled asthma. 
| Secondary endpoints
| Targeted vs untargeted treatment effects
Patients treated with grass AIT and exposed to birch pollen in the ACC showed a slight reduction in mean (95% CI) AUC adj TNSS of TA B L E 1 Baseline demographic characteristics (safety set)
| Change in birch/timothy grass IgG 4
Median (25th-75th) serum levels of grass pollen-specific IgG 
| Severity of allergy symptoms during pollen seasons
Patients treated with grass AIT had a slightly higher median (25th- 
| Safety results
The majority of patients reported mild (37. (Table S1 ).
F I G U R E 3
Overview of targeted and untargeted effects of allergen immunotherapy on total nasal symptom score (full analysis set). ACC, allergen challenge chamber; AIT, allergen immunotherapy; AUC, area under the curve; B-B, birch-on-birch treatment effect (targeted); B-G, birch-on-grass treatment effect (untargeted); CI, confidence interval; G-B, grass-on-birch treatment effect (untargeted); G-G, grasson-grass treatment effect (targeted); n, number of patients with data; TNSS, total nasal symptom score. Between-groups comparisons evaluate the utility of an "active allergen placebo"; within-group comparisons evaluate the specificity of the ACC measurement. P-value from 2-sided 1-sample t test. Results for the perprotocol set analysis were similar to full analysis set for all primary and secondary endpoints Grade 2). No TEAEs of WAO Grade 3 or higher were reported. In 36 patients (37.9%), the TEAEs were suspected to be related to IMP (Table 3 ) and in 6 patients (6.3%) were considered to be related to trial procedures (all related to ACC procedures). Overall, 3 patients experienced 7 serious TEAEs: 1 event (multiple sclerosis) in the grass AIT and 6 events (concussion, road traffic accident, tooth fracture, loss of consciousness, skin erosion, and ventricular extrasystoles) in the birch AIT, which led to discontinuation of 2 patients (multiple sclerosis and ventricular extrasystoles). No serious TEAEs were considered to be related to IMP or procedures.
| D ISCUSS I ON
Primary endpoint results demonstrated a treatment effect for grass and birch AIT-targeted treatments. As previously reported, 8, 9 both allergoid preparations were well tolerated, reduced the allergic TA B L E 2 Targeted and untargeted treatment effects on grass and birch AIT groups on the total nasal symptom score (full analysis set) Abbreviations: ACC, allergen challenge chamber; AIT, allergen immunotherapy; AUC, area under the curve; CI, confidence interval; Max, maximum; Min, minimum; N, number of patients; n, number of patients with data; Q, quartile; SD, standard deviation; TNSS, total nasal symptom score. *P-value from 2-sided 1-sample t test.
Grass AIT (N = 47) Birch AIT (N = 48) Overall (N = 95)
Events n (%) Events n (%) Events n (%) TA B L E 3 Overview of treatmentemergent adverse events (safety set) rhinoconjunctivitis symptoms, and induced an elevation of allergenspecific IgG 4 .
Additional key objectives of this trial were to compare treatment effects in the targeted and untargeted AITs, and testing the concept of an "active allergen placebo" vs a conventional placebo.
To this end, we compared the targeted treatment effect for grass and birch AIT to the untargeted treatment effect: between targeted treatment groups (ie, between the same allergens for ACC challenges in different AIT groups), within targeted treatment groups (ie, between different allergens for ACC challenges in the same AIT group), and combined (ie, both targeted treatments vs both untargeted).
When comparing targeted vs untargeted treatment effects (AUC adj TNSS) between AIT groups, which evaluates the utility of an "active allergen placebo," significant differences were observed for both allergens. On within-treatment group comparisons, which evaluate the specificity of the ACC measurement, the specificity 
12-14
Our study corroborates the ARIA-GA 2 LEN statement con- Although the use of an "active allergen placebo" is an attractive concept supported by our data, interpretation on specificity is limited and would have been more robust with the introduction of an additional classical placebo group. While this would have allowed to assess the specificity and sensitivity of ACC challenges, blinding problems with the classical placebo would have required a larger sample size for robust conclusions. The observed differences in specificity in grass-vs birch-AIT warrant more detailed studies, including stratified assessments according to response levels, to further establish the usability of an "active allergen placebo." Coupling molecular allergy testing with this study design might better define the study population sensitization profiles (including cross-reactions) and enhance the evaluation of clinical responses. Another limitation to be considered in this study design is the potential high number of patients that need to be screened to find suitable dual-allergic patients.
In conclusion, for patients suffering from dual allergies from distinct allergens, the active untargeted treatment is an adequate control group for the active targeted treatment. This finding has implications for future clinical trials as this trial design enables all patients to benefit from treatment, avoiding ethical concerns, improving blinding, and allowing longer trial durations.
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